|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
New hemophiliac medication: TT-103MH. All the studies have confirmed that TT-103MH is projected like the only approach to treat topical bleeding episodes in hemophiliacs' patients, even when a lethal hemorrhage is present.
New biotech drug for deep vein thrombosis symptoms. TT-105 is a monoclonal antibody that shows high potency, good selectivity and demonstrates high efficacy in ex-vivo human experiments and in several in vivo animal models.
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.
|
|
|
|
